Oncology

News

Merck taps Caris’ AI expertise in ADC-focused alliance

Germany’s Merck KGaA has partnered with techbio company Caris Discovery in a $1.4 billion alliance that will apply artificial intelligence to the design of antibody-drug c

News

Genmab offers $1.8bn for ADC specialist ProfoundBio

Antibody developer Genmab has made a play to boost its expertise in the scalding hot area of antibody-drug conjugates (ADCs), agreeing a $1.8 billion deal to acquire Profo

R&D

R&D in 2023 sees focus return to oncology

After the rush of research to find solutions to the pandemic, a recent report has found that pharma R&D has returned to its usual rhythms.

News

AZ, Daiichi Sankyo file Dato-DXd for second indication

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (

News

Ipsen licenses Sutro ADC in $900m deal

Ipsen has expanded its oncology pipeline by licensing rights to an antibody-drug conjugate (ADC) for solid tumours from Sutro Biopharma, its first drug in the category.

News

Japan clears first CLDN18.2 drug, Astellas’ Vyloy

Astellas has become the first drugmaker to bring a claudin 18.2 (CLDN18.2) targeted therapy to regulatory approval, getting a green light in Japan for Vyloy as a treatment

Merck taps Caris’ AI expertise in ADC-focused alliance

Genmab offers $1.8bn for ADC specialist ProfoundBio

R&D in 2023 sees focus return to oncology

AZ, Daiichi Sankyo file Dato-DXd for second indication

Ipsen licenses Sutro ADC in $900m deal

Japan clears first CLDN18.2 drug, Astellas’ Vyloy

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Oncology

Editor's Picks